Search
Rezivertinib
go.drugbank.com/drugs/DB21471InvestigationalRezivertinib has a monoisotopic molecular weight of 486.24 Da. … Rezivertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Rezivertinib is a epidermal growth factor receptor (EGFR) inhibitor.
19-Nor-5-androstenedione
go.drugbank.com/drugs/DB01443ExperimentalIllicitIt is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports. … 19-Nor-5-andorstenedione is a prohormone which has the potential to affect bodily levels of testosterone once metabolized in vivo.
Denibulin
go.drugbank.com/drugs/DB05932ExperimentalDenibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Ligelizumab
go.drugbank.com/drugs/DB11856InvestigationalSimilar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer … Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE).
Veligrotug
go.drugbank.com/drugs/DB18976Approved[L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the … Veligrotug is a humanized IgG1 monoclonal antibody that binds the insulin-like growth factor-1 receptor and blocks ligand-induced receptor autophosphorylation, interrupting IGF-1R signaling.
Synonyms: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human-Mus musculus monoclonal VRDN-001 γ1-chain), disulfide with human-Mus musculus monoclonal VRDN-001 κ-chain, dimerVH3739937
go.drugbank.com/drugs/DB25287InvestigationalVH3739937 is a small molecule drug. … (FE), and Drug-drug Interaction (DDI)).
GFT14
go.drugbank.com/drugs/DB05061ExperimentalGFT14 is a new class of medicaction for treatment of cardiometabolic disease. … GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin.
Rhein
go.drugbank.com/drugs/DB13174ExperimentalRhein is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in many medicinal plants including Rheum palmatum, Cassia tora, Polygonum multiflorum, and Aloe barbadensis [A19247] … It is known to have hepatoprotective, nephroprotective, anti-cancer, anti-inflammatory, and several other protective effects.
Foretinib
go.drugbank.com/drugs/DB12307InvestigationalForetinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. … Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others.